Skip to Content

Madrigal Pharmaceuticals Inc MDGL

Morningstar Rating
$277.59 +0.57 (0.21%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MDGL is trading at a 822% premium.
Price
$277.60
Fair Value
$884.87
Uncertainty
Extreme
1-Star Price
$1,814.82
5-Star Price
$85.89
Economic Moat
Bpn
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MDGL is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$277.02
Day Range
$268.07280.00
52-Week Range
$119.76299.98
Bid/Ask
$250.00 / $285.01
Market Cap
$5.92 Bil
Volume/Avg
418,093 / 550,942

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
376

Comparables

Valuation

Metric
MDGL
CBAY
MORF
Price/Earnings (Normalized)
Price/Book Value
6.7512.652.00
Price/Sales
111.01
Price/Cash Flow
Price/Earnings
MDGL
CBAY
MORF

Financial Strength

Metric
MDGL
CBAY
MORF
Quick Ratio
9.2610.7037.20
Current Ratio
9.3910.9638.17
Interest Coverage
−31.95−5.27
Quick Ratio
MDGL
CBAY
MORF

Profitability

Metric
MDGL
CBAY
MORF
Return on Assets (Normalized)
−74.33%−30.06%−18.85%
Return on Equity (Normalized)
−125.94%−51.97%−19.43%
Return on Invested Capital (Normalized)
−95.71%−30.87%−23.26%
Return on Assets
MDGL
CBAY
MORF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
BszcyrjlyZctlnvd$124.1 Bil
Regeneron Pharmaceuticals Inc
REGN
VwsjwltNnmwh$114.2 Bil
Moderna Inc
MRNA
QpxzkbzmdQdjq$53.7 Bil
argenx SE ADR
ARGX
GrtwdkdzSpdv$23.0 Bil
BioNTech SE ADR
BNTX
XxzlsjkYxvd$22.2 Bil
Alnylam Pharmaceuticals Inc
ALNY
YnknzphQxlhzzr$20.3 Bil
Biomarin Pharmaceutical Inc
BMRN
JxhcgnvgjRhkkzq$15.9 Bil
United Therapeutics Corp
UTHR
XzvwkykqQhft$12.8 Bil
Incyte Corp
INCY
WpqzgdfkCfkwrzn$12.2 Bil
Royalty Pharma PLC Class A
RPRX
XhgcjhssclVhrrnjf$12.2 Bil

Sponsor Center